alpha 1 Catenin (CTNNA1) (NM_001903) Human Over-expression Lysate

CAT#: LC400708

CTNNA1 HEK293T cell transient overexpression lysate (as WB positive control)

Product Images

Western blot validation of overexpression lysate (Cat# LY400708) using anti-DDK antibody (Cat# TA50011-100). Left: Cell lysates from un-transfected HEK293T cells; Right: Cell lysates from HEK293T cells transfected with RC201766 using transfection reagent MegaTran 2.0 (Cat# TT210002).

Specifications

Product Data

• Species: Human
• Expression Host: HEK293T
• Expression cDNA Clone or AA Sequence: TrueORF Clone RC201766
• Tag: C-Myc/DDK
• Detection Antibodies: Clone OTI4C5, Anti-DDK (FLAG) monoclonal antibody (TA50011-100)
• Accession Number: NM_001903, NP_001894
• Other Names: CAP102; MDPT2
• Predicted MW: 100.1 kDa
• Components: 1 vial of 20 ug lyophilized gene specific transient over-expression cell lysate
• Storage: The lysate can be shipped at ambient temperature. Upon receiving, store the sample at -20°C. Lysate samples can be reconstituted with SDS Sample Buffer. Avoid repeated freeze-thaw cycles after reconstitution. Lysate samples are stable for 12 months from date of receipt when stored at -20°C.
• Preparation: HEK293T cells in 10-cm dishes were transiently transfected with MegaTran Transfection Reagent (TT200002) and 5ug TrueORF cDNA plasmid. Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer (25mM Tris-HCl pH7.6, 150mM NaCl, 1% NP-40, 1mM EDTA, 1xProteinase inhibitor cocktail mix (Sigma), 1mM PMSF and 1mM Na3VO4), and then centrifuged to clarify the lysate. Protein concentration was measured by BCA kit (Thermo Scientific Inc.). To facilitate transportation and protein, the products are supplied as lyophilized proteins.

Reference Data

• RefSeq: NP_001894
• Locus ID: 1495
• Cytogenetics: 5q31.2
• Protein Families: Druggable Genome
• Protein Pathways: Adherens junction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Endometrial cancer, Leukocyte transendothelial migration, Pathways in cancer, Tight junction